Can i use kesimpta if i have a history of hepatitis?

Can You Use Kesimpta with Hepatitis History?

Kesimpta (ofatumumab), an anti-CD20 monoclonal antibody for relapsing multiple sclerosis, carries risks for patients with hepatitis B history. The prescribing information contraindicates it in those with active hepatitis B virus (HBV) infection due to reactivation risk, which can cause fulminant hepatitis, hepatic failure, or death.[1] For carriers or those with resolved HBV (HBsAg negative, anti-HBc positive), test HBV DNA levels before starting; if positive, delay treatment until negative or consult hepatology.[1]

Hepatitis B Screening and Monitoring Requirements

All patients must be screened for HBV, hepatitis C (HCV), and tuberculosis before Kesimpta initiation.[1]
- HBV carriers: Antiviral prophylaxis is recommended during and for up to 12 months after treatment to prevent reactivation.[1]
- HCV history: No specific contraindication, but monitor liver function; Kesimpta does not directly worsen HCV but immunosuppression raises infection risks.[1]
Reactivation has occurred in 0.04% of clinical trial patients despite screening.[1]

What Happens During Reactivation?

HBV reactivation involves viral replication surge from B-cell depletion, leading to liver enzyme elevation (ALT >3x upper limit). Symptoms include fatigue, jaundice, or acute liver failure. In trials and post-marketing, rare fatalities occurred.[1] Monitor ALT and HBV DNA every 3-6 months during therapy, plus 8-12 months post-treatment.[1]

Alternatives for MS Patients with Hepatitis History

• Ocrevus (ocrelizumab): Similar anti-CD20; same HBV warnings and screening—avoid in active HBV.[2]
  
• B-cell therapies like Rituxan (rituximab): Carry identical reactivation black box warning.[3]
  
• Non-B-cell options: Interferon beta, glatiramer acetate, or S1P modulators (e.g., fingolimod) have lower HBV risks but different efficacy profiles.[4] Discuss with neurologist for personalized switch.
  
  

Steps Before Starting Treatment

1. Get HBV serology (HBsAg, anti-HBc, anti-HBs) and HBV DNA PCR.
   
2. If high reactivation risk, start entecavir or tenofovir prophylaxis.
   
3. Vaccinate HBV-susceptible patients pre-treatment.[1]
   Always consult a doctor; self-assessment risks severe outcomes.
   
   Sources:
   [1] Kesimpta Prescribing Information (Novartis)
   [2] Ocrevus Prescribing Information (Genentech)
   [3] Rituxan Prescribing Information (Genentech)
   [4] MS Treatment Guidelines (National MS Society)